Rx (Prescription Medicine)
USD $ 120.00
Bufatas IV 60mg Injection 是一种含有活性成分 Bufetasam 的药物。它主要用于治疗某些类型的癌症，尤其是激素敏感性癌症。Bufetasam 通过作为芳香化酶抑制剂发挥作用。它阻断酶 aromatase，该酶负责在体内将雄激素转化为雌激素。通过降低雌激素水平，Bufatas IV 有助于减缓或阻止雌激素依赖性癌细胞的生长，例如某些类型的乳腺癌细胞。
Bufatas IV 60mg Injection 的典型用法和剂量由医疗专业人员根据具体病情、患者的反应以及其他个体因素确定。该药物通过静脉给药。常见的副作用可能包括潮热、疲劳、关节疼痛、恶心和头痛。少见但更严重的副作用也可能发生，患者应立即向医生报告任何令人担忧的症状。Bufatas IV 应储存在室温，避光防潮处。正确使用此药物必须在合格医疗专业人员的监督下进行。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 60 Mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Busulfan 60 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
